FFTY:NYE-Innovator IBD® 50 ETF (USD)

ETF | Mid-Cap Growth |

Last Closing

USD 26.52

Change

-0.38 (-1.41)%

Market Cap

N/A

Volume

0.08M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-01 )

Largest Industry Peers for Mid-Cap Growth

Symbol Name Price(Change) Market Cap
IWP iShares Russell Mid-Cap Growth..

-0.89 (-0.76%)

USD 14.94B
VOT Vanguard Mid-Cap Growth Index ..

-1.99 (-0.82%)

USD 14.12B
IJK iShares S&P Mid-Cap 400 Growth..

-0.67 (-0.73%)

USD 9.84B
XMMO Invesco S&P MidCap Momentum ET..

-0.48 (-0.40%)

USD 2.43B
IVOG Vanguard S&P Mid-Cap 400 Growt..

-0.70 (-0.61%)

USD 1.08B
ETHO Amplify ETF Trust

-0.88 (-1.47%)

USD 0.18B
CWS AdvisorShares Focused Equity E..

-0.35 (-0.51%)

USD 0.17B
IPO Renaissance IPO ETF

-0.92 (-2.15%)

USD 0.15B
BFOR Barron's 400 ETF

-0.49 (-0.68%)

USD 0.15B
PEXL Pacer US Export Leaders ETF

-0.52 (-1.03%)

USD 0.07B

ETFs Containing FFTY

N/A

Market Performance

  Market Performance vs. Industry/Classification (Mid-Cap Growth) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.82% 19% F 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.82% 19% F 45% F
Trailing 12 Months  
Capital Gain 22.04% 28% F 57% F
Dividend Return 0.72% 44% F 7% C-
Total Return 22.77% 28% F 50% F
Trailing 5 Years  
Capital Gain -16.96% 11% F 24% F
Dividend Return 2.68% 33% F 8% B-
Total Return -14.28% 11% F 16% F
Average Annual (5 Year Horizon)  
Capital Gain -1.86% N/A N/A 27% F
Dividend Return -1.20% N/A N/A 18% F
Total Return 0.66% N/A N/A 16% F
Risk Return Profile  
Volatility (Standard Deviation) 29.56% N/A N/A 35% F
Risk Adjusted Return -4.05% N/A N/A 22% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike